Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after progression during treatment with other targeted therapies

AIM: The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic renal cell carcinoma (mRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. METHODS: We retrospectively e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Matrana, M. R., Duran, C., Shetty, A., Xiao, L., Atkinson, B. J., Corn, P., Pagliaro, L. C., Millikan, R. E., Charnsangavej, C., Jonasch, E., Tannir, N. M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882156/
https://ncbi.nlm.nih.gov/pubmed/23810246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2013.06.003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge